Ipsen, a worldwide biopharmaceutical firm with an emphasis on getting groundbreaking medicines to patients in three remedial regions: oncology, interesting sickness and neuroscience, has reported confirmation of an extended partnership and license...
Bone Health Technologies (BHT), a leading medtech innovator developing breakthrough noninvasive and drug-free solutions for low bone density, announced the company has been awarded a fifth patent for Osteoboost—the first and only FDA-cleared...
Sanofi and Regeneron received European Union permission for the expanded use of their Dupixent injection in patients with chronic lung disease, a rare instance of the EU clearing a medicine faster than the United States. The EU Commission...
Sobi declared the commencement of a rolling Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for SEL-212. The pivotal studies DISSOLVE I and II served as the foundation for the submission. For the treatment of...
Kedrion Biopharma Inc., a biopharmaceutical firm, declared that it has established the framework for a long-term partnership with Biotest AG for the complete commercialization and marketing of the immunoglobulin therapy Yimmugo in the United...
PharmAbcine, Inc, a clinical-stage firm developing next generation therapeutics to treat medical needs, declared the decision to accelerate PMC-403, its candidate treatment for neovascular age-related macular degeneration (nAMD), to the fourth...
.jpg)
